
|Articles|April 15, 2003
Antibiotic combats acute bacterial conjunctivitis
Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
AAO 2025: Understanding and diagnosing endophthalmitis
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5